相关实验视频
Updated: May 5, 2026

12:03
Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
28.7K
皮肤冠状动脉干预后对降脂剂的药物坚持:荷兰全国实况数据
Marijke J C Timmermans1, M Patrick Witvliet2, Judith A van Erkelens3
1Netherlands Heart Registration, Utrecht, The Netherlands. marijke.timmermans@nhr.nl.
概括
在皮肤冠状动脉干预 (PCI) 后,降脂药物的坚持率在第一年约为71%-76%. 妇女和老年患者的坚持率较低,他类药物的使用量下降,而以泽胺和PCSK9抑制剂的使用量增加.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 降脂药物对于减少心血管事件和死亡率至关重要.
- 患者遵守降脂疗法仍然是一个重大挑战.
- 了解穿皮冠状动脉干预 (PCI) 后的坚持模式对于优化心血管护理至关重要.
研究的目的:
- 评估急性和选择性PCI后第一年降脂药物坚持率.
- 分析不同类别和亚型的降脂药物的坚持趋势.
- 为了确定与较低的坚持相关的患者人口统计学.
主要方法:
- 使用荷兰全国性索赔数据库 (Vektis) 的回顾性队列研究.
- 在2018年至2020年期间,包括97,176名接受PCI的患者.
- 药物持有率定义为药物持有率为80%或更高.
主要成果:
- 选择性PCI后的第一年坚持率为71-73%;急性PCI后的坚持率为74-76%.
- 治疗以谢胺和PCSK9抑制剂的坚持增加,而他类药物的坚持在一年内下降.
- 在女性和80岁及以上的患者中观察到较低的坚持.
结论:
- 在PCI后的一年,降脂药物的坚持是不理想的,特别是在特定的人口群体中.
- 趋势表明,在第一年,从他类药物转向以泽胺和PCSK9抑制剂.
- 可能需要有针对性的干预措施来改善脆弱患者群体的坚持.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Angina IV: Management
493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Peripheral Artery Disease III: Interprofessional Care
655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655

